Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia

Genes Chromosomes and Cancer

Volumn 51, Issue 12, 2012, Pages 1125-1132

  Ouillette, Peter ^a   Li, Jinghui ^a   Shaknovich, Rita ^b   Li, Yifeng ^a   Melnick, Ari ^b   Shedden, Kerby ^c   Malek, Sami N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ATM PROTEIN;

ARTICLE; ATM GENE; CANCER SURVIVAL; CHROMOSOME 11Q; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; EXON; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE SEQUENCE; HUMAN; INCIDENCE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; COHORT STUDIES; DNA-BINDING PROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 84867231324     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21997     Document Type: Article

References (24)

1. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J, Taylor AM, Fegan C, Moss P, Stankovic T. 2005. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106: 3175-3182.
2. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, Majid A, Dyer M, Siebert R, Taylor AM, Moss PA, Stankovic T. 2007. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 25: 5448-5457.
3. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506.
4. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, Albitar M, Reed JC, Croce CM. 1999. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 59: 24-27.
5. Chiorazzi N, Ferrarini M. 2011. Cellular origin(s) of chronic lymphocytic leukemia: Cautionary notes and additional considerations and possibilities. Blood 117: 1781-1791.
6. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916.
7. Fegan C, Robinson H, Thompson P, Whittaker JA, White D. 1995. Karyotypic evolution in CLL: Identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 9: 2003-2008.
8. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps TJ, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM. 2011. Tcl1 interacts with Atm and enhances NF-kB activation in hematological malignancies. Blood 119: 180-187.
9. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. 2009. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 114: 4675-4686.
10. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ, Parker AC, Castoldi GL, Guneo A, Knuutila S, Elonen E, Gahrton G. 1990. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 323: 720-724.
11. Lozanski G, Ruppert AS, Heerem NA, Lozanski A, Luca DM, Gordon A, Gribben JG, Morrison VA, Rai KM, Marcucci G, Larson RA, Byrd JC. Variations of the ATM gene in chronic lymphocytic leukemia patients lack substantial impact on progression-free survival and overall survival: A Cancer and Leukemia Group B Study. Leuk Lymphoma (in press).
12. Ouillette P, Fossum S, Parkin B, Ding L, Bockenstedt P, Al-Zoubi A, Shedden K, Malek SN. 2010. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res 16: 835-847.
13. Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, Talpaz M, Kaminski M, Li C, Shedden K, Malek SN. 2011. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 118: 3051-3061.
14. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Gine E, Hernandez JM, Gonzalez-Diaz M, Puente DA, Velasco G, Freije JM, Tubio JM, Royo R, Gelpi JL, Orozco M, Pisano DG, Zamora J, Vazquez M, Valencia A, Himmelbauer H, Bayes M, Heath S, Gut M, Gut I, Estivill X, Lopez-Guillermo A, Puente XS, Campo E, Lopez-Otin C. 2011. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44: 47-52.
15. Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L, Erba H, Campagnaro E, Shedden K, Kaminski M, Malek SN. 2011. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res 17: 2679-2692.
16. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. 1999. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94: 748-753.
17. Shaknovich R, Figueroa ME, Melnick A. 2010. HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. Methods Mol Biol 632: 191-201.
18. Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J, Jelinek DF, Kay NE. 2008. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 26: e5-6.
19. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ, Moss PA, Taylor AM. 1999. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 353: 26-29.
20. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M. 1998. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 58: 4552-4557.
21. Thompson RF, Reimers M, Khulan B, Gissot M, Richmond TA, Chen Q, Zheng X, Kim K, Greally JM. 2008. An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics 24: 1161-1167.
22. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. 2011. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365: 2497-2506.
23. Yuille MR, Condie A, Hudson CD, Bradshaw PS, Stone EM, Matutes E, Catovsky D, Houlston RS. 2002. ATM mutations are rare in familial chronic lymphocytic leukemia. Blood 100: 603-609.
24. Zhang X, Reis M, Khoriaty R, Li Y, Ouillette P, Samayoa J, Carter H, Karchin R, Li M, Diaz LA, Jr., Velculescu VE, Papadopoulos N, Kinzler KW, Vogelstein B, Malek SN. 2011. Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. Leukemia 25: 1908-1910.